Bausch+Lomb IPO Presentation Deck

Significant opportunity Indication Dry eye Myopia Ocular inflammation Age-related macular degeneration BAUSCH+ LOMB for transformational growth Pipeline Product Hva OvdAS nally XIPERE NOV03 Expected Launch: 2023 Low dose atropine spray Expected Launch: 2027 Xipere ™M Launch: 1Q22 Ranibizumab biosimilar Expected Launch: 2023 OPHTHALMIC PHARMACEUTICALS Differentiation Potentially first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction U.S. gross market for Rx dry eye products in 2020 = $3.09B¹ Potentially first-in-class topical treatment for the reduction of pediatric myopia progression. Microdose administration is designed to result in low systemic and ocular drug exposure Myopia affects ~25M U.S. children, with up to 3M considered to be at risk for high myopia² First and only therapy available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis Annual prevalence of treated Uveitis patients (18+) in U.S. -125K³ Participating in the growing biosimilar market with ranibizumab allows us to expand patient access to treatments for retinal vascular disorders U.S. anti-VEGF Revenue in 2020 = - $6.5B4 1. Source: 2020, IQVIA 2. Source: Theophanous C. Myopia Prevalence and Risk Factors in Children Clinical Ophthalmology. December 2018 and U.S. Census Bureau, Current Population Survey, Annual Social and Economic Supplement, 2019. 3. Source: Thorne JE, et al. 2016. JAMA Ophthalmology, Chu, et al 2013 Journal of Ophthalmic Inflammation and Infection 2013 4. Source: Based on reported 2020 sales of EYLEA and Lucentis per Regeneron and Roche public filings, respectively 32

View entire presentation